Triple combination of hepatic arterial infusion chemotherapy, immune checkpoint inhibitors, and tyrosine kinase inhibitors for treatment of advanced hepatocellular carcinoma: more robust evidence is still needed
1 Middle East Liver Diseases Center, Tehran, Iran.
2 Karsh Division of Gastroenterology and Hepatology, Cedars-Sinai Medical Center, Los Angeles, CA, USA; Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA, USA; Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.